カテゴリ： 世界, 医療/バイオ, QYResearch

注射可能型発作治療薬の世界市場2023年：ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他

■ 英語タイトル：Global Injectable Seizure Drugs Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7989）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7989
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療機器
■ ページ数：96
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[注射可能型発作治療薬の世界市場2023年：ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料は注射可能型発作治療薬のグローバル市場について調査・分析し、世界の注射可能型発作治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他）、用途別セグメント分析（病院薬局、小売店、オンライン薬局、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Pfizer Inc.、GW Pharmaceuticals plc、UCB S.A.、Eisai Co.Ltd.、Sunovion Pharmaceuticals Inc.、H. Lundbeck A/S、GlaxoSmithKline plc、Sandoz Inc.、Omega Laboratories Ltd ERFA Canada 2012 Inc.、Lundbeck Pharmaceuticals Llc、Fresenius Kabi、Mylan Pharmaceuticals、Hoffmann La andなどが含まれています。注射可能型発作治療薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、注射可能型発作治療薬市場規模を算出する際に考慮しました。

・注射可能型発作治療薬市場の概要
- 製品の定義
- 注射可能型発作治療薬の種類別セグメント
- 世界の注射可能型発作治療薬市場規模：タイプ別分析（ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他）
- 注射可能型発作治療薬の用途別セグメント
- 世界の注射可能型発作治療薬市場規模：用途別分析（病院薬局、小売店、オンライン薬局、その他）
- 世界の注射可能型発作治療薬市場規模予測（2018年-2029年）
- 注射可能型発作治療薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 注射可能型発作治療薬市場の競争状況およびトレンド

・注射可能型発作治療薬の地域別市場規模
- 北米の注射可能型発作治療薬市場規模（2018年-2029年）
- 米国の注射可能型発作治療薬市場規模（2018年-2029年）
- ヨーロッパの注射可能型発作治療薬市場規模（2018年-2029年）
- アジア太平洋の注射可能型発作治療薬市場規模（2018年-2029年）
- 中国の注射可能型発作治療薬市場規模（2018年-2029年）
- 日本の注射可能型発作治療薬市場規模（2018年-2029年）
- 韓国の注射可能型発作治療薬市場規模（2018年-2029年）
- インドの注射可能型発作治療薬市場規模（2018年-2029年）
- オーストラリアの注射可能型発作治療薬市場規模（2018年-2029年）
- 中南米の注射可能型発作治療薬市場規模（2018年-2029年）
- 中東・アフリカの注射可能型発作治療薬市場規模（2018年-2029年）

・種類別セグメント：ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他
- 世界の注射可能型発作治療薬のタイプ別販売量（2018年-2023年）
- 世界の注射可能型発作治療薬のタイプ別売上（2018年-2023年）
- 世界の注射可能型発作治療薬のタイプ別価格

・用途別セグメント：病院薬局、小売店、オンライン薬局、その他
- 世界の注射可能型発作治療薬の用途別販売量（2018年-2023年）
- 世界の注射可能型発作治療薬の用途別売上（2018年-2023年）
- 世界の注射可能型発作治療薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Pfizer Inc.、GW Pharmaceuticals plc、UCB S.A.、Eisai Co.Ltd.、Sunovion Pharmaceuticals Inc.、H. Lundbeck A/S、GlaxoSmithKline plc、Sandoz Inc.、Omega Laboratories Ltd ERFA Canada 2012 Inc.、Lundbeck Pharmaceuticals Llc、Fresenius Kabi、Mylan Pharmaceuticals、Hoffmann La and

・産業チェーンと販売チャネルの分析
- 注射可能型発作治療薬産業チェーン分析
- 注射可能型発作治療薬の主要原材料
- 注射可能型発作治療薬の販売チャネル
- 注射可能型発作治療薬のディストリビューター
- 注射可能型発作治療薬の主要顧客

・注射可能型発作治療薬市場ダイナミクス
- 注射可能型発作治療薬の業界動向
- 注射可能型発作治療薬市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Injectable Seizure Drugs Market Segmented By Drug Type such as Fosphenytoin, Midazolam, Carbamazepine, Cenobamate, Gabapentin, Phenytoin, Lamotrigine, Topiramate, Levetiracetam, Clobazam, Diazepam having Therapy such as Monotherapy and Combination Therapy
Highlights
The global Injectable Seizure Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Injectable Seizure Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Injectable Seizure Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Injectable Seizure Drugs include Pfizer Inc., GW Pharmaceuticals plc, UCB S.A., Eisai Co.Ltd., Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Sandoz Inc. and Omega Laboratories Ltd ERFA Canada 2012 Inc., etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Injectable Seizure Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Injectable Seizure Drugs.
The Injectable Seizure Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Injectable Seizure Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Injectable Seizure Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Pfizer Inc.
GW Pharmaceuticals plc
UCB S.A.
Eisai Co.Ltd.
Sunovion Pharmaceuticals Inc.
H. Lundbeck A/S
GlaxoSmithKline plc
Sandoz Inc.
Omega Laboratories Ltd ERFA Canada 2012 Inc.
Lundbeck Pharmaceuticals Llc
Fresenius Kabi
Mylan Pharmaceuticals
Hoffmann La and
Segment by Type
Fosphenytoin
Midazolam
Carbamazepine
Cenobamate
Gabapentin
Phenytoin
Lamotrigine
Topiramate
Levetiracetam
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Injectable Seizure Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Injectable Seizure Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Injectable Seizure Drugs Market Overview
1.1 Product Overview and Scope of Injectable Seizure Drugs
1.2 Injectable Seizure Drugs Segment by Type
1.2.1 Global Injectable Seizure Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Fosphenytoin
1.2.3 Midazolam
1.2.4 Carbamazepine
1.2.5 Cenobamate
1.2.6 Gabapentin
1.2.7 Phenytoin
1.2.8 Lamotrigine
1.2.9 Topiramate
1.2.10 Levetiracetam
1.2.11 Others
1.3 Injectable Seizure Drugs Segment by Application
1.3.1 Global Injectable Seizure Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Injectable Seizure Drugs Market Size Estimates and Forecasts
1.4.1 Global Injectable Seizure Drugs Revenue 2018-2029
1.4.2 Global Injectable Seizure Drugs Sales 2018-2029
1.4.3 Global Injectable Seizure Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Injectable Seizure Drugs Market Competition by Manufacturers
2.1 Global Injectable Seizure Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Injectable Seizure Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Injectable Seizure Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Injectable Seizure Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Injectable Seizure Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Injectable Seizure Drugs, Product Type & Application
2.7 Injectable Seizure Drugs Market Competitive Situation and Trends
2.7.1 Injectable Seizure Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Injectable Seizure Drugs Players Market Share by Revenue
2.7.3 Global Injectable Seizure Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Injectable Seizure Drugs Retrospective Market Scenario by Region
3.1 Global Injectable Seizure Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Injectable Seizure Drugs Global Injectable Seizure Drugs Sales by Region: 2018-2029
3.2.1 Global Injectable Seizure Drugs Sales by Region: 2018-2023
3.2.2 Global Injectable Seizure Drugs Sales by Region: 2024-2029
3.3 Global Injectable Seizure Drugs Global Injectable Seizure Drugs Revenue by Region: 2018-2029
3.3.1 Global Injectable Seizure Drugs Revenue by Region: 2018-2023
3.3.2 Global Injectable Seizure Drugs Revenue by Region: 2024-2029
3.4 North America Injectable Seizure Drugs Market Facts & Figures by Country
3.4.1 North America Injectable Seizure Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Injectable Seizure Drugs Sales by Country (2018-2029)
3.4.3 North America Injectable Seizure Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Injectable Seizure Drugs Market Facts & Figures by Country
3.5.1 Europe Injectable Seizure Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Injectable Seizure Drugs Sales by Country (2018-2029)
3.5.3 Europe Injectable Seizure Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Injectable Seizure Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Injectable Seizure Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Injectable Seizure Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Injectable Seizure Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Injectable Seizure Drugs Market Facts & Figures by Country
3.7.1 Latin America Injectable Seizure Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Injectable Seizure Drugs Sales by Country (2018-2029)
3.7.3 Latin America Injectable Seizure Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Injectable Seizure Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Injectable Seizure Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Injectable Seizure Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Injectable Seizure Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Injectable Seizure Drugs Sales by Type (2018-2029)
4.1.1 Global Injectable Seizure Drugs Sales by Type (2018-2023)
4.1.2 Global Injectable Seizure Drugs Sales by Type (2024-2029)
4.1.3 Global Injectable Seizure Drugs Sales Market Share by Type (2018-2029)
4.2 Global Injectable Seizure Drugs Revenue by Type (2018-2029)
4.2.1 Global Injectable Seizure Drugs Revenue by Type (2018-2023)
4.2.2 Global Injectable Seizure Drugs Revenue by Type (2024-2029)
4.2.3 Global Injectable Seizure Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Injectable Seizure Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Injectable Seizure Drugs Sales by Application (2018-2029)
5.1.1 Global Injectable Seizure Drugs Sales by Application (2018-2023)
5.1.2 Global Injectable Seizure Drugs Sales by Application (2024-2029)
5.1.3 Global Injectable Seizure Drugs Sales Market Share by Application (2018-2029)
5.2 Global Injectable Seizure Drugs Revenue by Application (2018-2029)
5.2.1 Global Injectable Seizure Drugs Revenue by Application (2018-2023)
5.2.2 Global Injectable Seizure Drugs Revenue by Application (2024-2029)
5.2.3 Global Injectable Seizure Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Injectable Seizure Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer Inc.
6.1.1 Pfizer Inc. Corporation Information
6.1.2 Pfizer Inc. Description and Business Overview
6.1.3 Pfizer Inc. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Inc. Injectable Seizure Drugs Product Portfolio
6.1.5 Pfizer Inc. Recent Developments/Updates
6.2 GW Pharmaceuticals plc
6.2.1 GW Pharmaceuticals plc Corporation Information
6.2.2 GW Pharmaceuticals plc Description and Business Overview
6.2.3 GW Pharmaceuticals plc Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GW Pharmaceuticals plc Injectable Seizure Drugs Product Portfolio
6.2.5 GW Pharmaceuticals plc Recent Developments/Updates
6.3 UCB S.A.
6.3.1 UCB S.A. Corporation Information
6.3.2 UCB S.A. Description and Business Overview
6.3.3 UCB S.A. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 UCB S.A. Injectable Seizure Drugs Product Portfolio
6.3.5 UCB S.A. Recent Developments/Updates
6.4 Eisai Co.Ltd.
6.4.1 Eisai Co.Ltd. Corporation Information
6.4.2 Eisai Co.Ltd. Description and Business Overview
6.4.3 Eisai Co.Ltd. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Eisai Co.Ltd. Injectable Seizure Drugs Product Portfolio
6.4.5 Eisai Co.Ltd. Recent Developments/Updates
6.5 Sunovion Pharmaceuticals Inc.
6.5.1 Sunovion Pharmaceuticals Inc. Corporation Information
6.5.2 Sunovion Pharmaceuticals Inc. Description and Business Overview
6.5.3 Sunovion Pharmaceuticals Inc. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sunovion Pharmaceuticals Inc. Injectable Seizure Drugs Product Portfolio
6.5.5 Sunovion Pharmaceuticals Inc. Recent Developments/Updates
6.6 H. Lundbeck A/S
6.6.1 H. Lundbeck A/S Corporation Information
6.6.2 H. Lundbeck A/S Description and Business Overview
6.6.3 H. Lundbeck A/S Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 H. Lundbeck A/S Injectable Seizure Drugs Product Portfolio
6.6.5 H. Lundbeck A/S Recent Developments/Updates
6.7 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxoSmithKline plc Injectable Seizure Drugs Product Portfolio
6.7.5 GlaxoSmithKline plc Recent Developments/Updates
6.8 Sandoz Inc.
6.8.1 Sandoz Inc. Corporation Information
6.8.2 Sandoz Inc. Description and Business Overview
6.8.3 Sandoz Inc. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sandoz Inc. Injectable Seizure Drugs Product Portfolio
6.8.5 Sandoz Inc. Recent Developments/Updates
6.9 Omega Laboratories Ltd ERFA Canada 2012 Inc.
6.9.1 Omega Laboratories Ltd ERFA Canada 2012 Inc. Corporation Information
6.9.2 Omega Laboratories Ltd ERFA Canada 2012 Inc. Description and Business Overview
6.9.3 Omega Laboratories Ltd ERFA Canada 2012 Inc. Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Omega Laboratories Ltd ERFA Canada 2012 Inc. Injectable Seizure Drugs Product Portfolio
6.9.5 Omega Laboratories Ltd ERFA Canada 2012 Inc. Recent Developments/Updates
6.10 Lundbeck Pharmaceuticals Llc
6.10.1 Lundbeck Pharmaceuticals Llc Corporation Information
6.10.2 Lundbeck Pharmaceuticals Llc Description and Business Overview
6.10.3 Lundbeck Pharmaceuticals Llc Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Lundbeck Pharmaceuticals Llc Injectable Seizure Drugs Product Portfolio
6.10.5 Lundbeck Pharmaceuticals Llc Recent Developments/Updates
6.11 Fresenius Kabi
6.11.1 Fresenius Kabi Corporation Information
6.11.2 Fresenius Kabi Injectable Seizure Drugs Description and Business Overview
6.11.3 Fresenius Kabi Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Fresenius Kabi Injectable Seizure Drugs Product Portfolio
6.11.5 Fresenius Kabi Recent Developments/Updates
6.12 Mylan Pharmaceuticals
6.12.1 Mylan Pharmaceuticals Corporation Information
6.12.2 Mylan Pharmaceuticals Injectable Seizure Drugs Description and Business Overview
6.12.3 Mylan Pharmaceuticals Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Mylan Pharmaceuticals Injectable Seizure Drugs Product Portfolio
6.12.5 Mylan Pharmaceuticals Recent Developments/Updates
6.13 Hoffmann La and
6.13.1 Hoffmann La and Corporation Information
6.13.2 Hoffmann La and Injectable Seizure Drugs Description and Business Overview
6.13.3 Hoffmann La and Injectable Seizure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Hoffmann La and Injectable Seizure Drugs Product Portfolio
6.13.5 Hoffmann La and Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Injectable Seizure Drugs Industry Chain Analysis
7.2 Injectable Seizure Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Injectable Seizure Drugs Production Mode & Process
7.4 Injectable Seizure Drugs Sales and Marketing
7.4.1 Injectable Seizure Drugs Sales Channels
7.4.2 Injectable Seizure Drugs Distributors
7.5 Injectable Seizure Drugs Customers
8 Injectable Seizure Drugs Market Dynamics
8.1 Injectable Seizure Drugs Industry Trends
8.2 Injectable Seizure Drugs Market Drivers
8.3 Injectable Seizure Drugs Market Challenges
8.4 Injectable Seizure Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Injectable Seizure Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Injectable Seizure Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Injectable Seizure Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Injectable Seizure Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Injectable Seizure Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Injectable Seizure Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Injectable Seizure Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Injectable Seizure Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Injectable Seizure Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Injectable Seizure Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Injectable Seizure Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Injectable Seizure Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Injectable Seizure Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Injectable Seizure Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Injectable Seizure Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Injectable Seizure Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Injectable Seizure Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Injectable Seizure Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global Injectable Seizure Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Injectable Seizure Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Injectable Seizure Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Injectable Seizure Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Injectable Seizure Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Injectable Seizure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Injectable Seizure Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Injectable Seizure Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America Injectable Seizure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Injectable Seizure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Injectable Seizure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Injectable Seizure Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Injectable Seizure Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe Injectable Seizure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Injectable Seizure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Injectable Seizure Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Injectable Seizure Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Injectable Seizure Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Injectable Seizure Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Injectable Seizure Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Injectable Seizure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Injectable Seizure Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Injectable Seizure Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Injectable Seizure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Injectable Seizure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Injectable Seizure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Injectable Seizure Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Injectable Seizure Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Injectable Seizure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Injectable Seizure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Injectable Seizure Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Injectable Seizure Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global Injectable Seizure Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Injectable Seizure Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Injectable Seizure Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Injectable Seizure Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Injectable Seizure Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Injectable Seizure Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Injectable Seizure Drugs Price (US$/Unit) by Type (2018-2023)
Table 59. Global Injectable Seizure Drugs Price (US$/Unit) by Type (2024-2029)
Table 60. Global Injectable Seizure Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Injectable Seizure Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global Injectable Seizure Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Injectable Seizure Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Injectable Seizure Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Injectable Seizure Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Injectable Seizure Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Injectable Seizure Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Injectable Seizure Drugs Price (US$/Unit) by Application (2018-2023)
Table 69. Global Injectable Seizure Drugs Price (US$/Unit) by Application (2024-2029)
Table 70. Pfizer Inc. Corporation Information
Table 71. Pfizer Inc. Description and Business Overview
Table 72. Pfizer Inc. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Inc. Injectable Seizure Drugs Product
Table 74. Pfizer Inc. Recent Developments/Updates
Table 75. GW Pharmaceuticals plc Corporation Information
Table 76. GW Pharmaceuticals plc Description and Business Overview
Table 77. GW Pharmaceuticals plc Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. GW Pharmaceuticals plc Injectable Seizure Drugs Product
Table 79. GW Pharmaceuticals plc Recent Developments/Updates
Table 80. UCB S.A. Corporation Information
Table 81. UCB S.A. Description and Business Overview
Table 82. UCB S.A. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. UCB S.A. Injectable Seizure Drugs Product
Table 84. UCB S.A. Recent Developments/Updates
Table 85. Eisai Co.Ltd. Corporation Information
Table 86. Eisai Co.Ltd. Description and Business Overview
Table 87. Eisai Co.Ltd. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Eisai Co.Ltd. Injectable Seizure Drugs Product
Table 89. Eisai Co.Ltd. Recent Developments/Updates
Table 90. Sunovion Pharmaceuticals Inc. Corporation Information
Table 91. Sunovion Pharmaceuticals Inc. Description and Business Overview
Table 92. Sunovion Pharmaceuticals Inc. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sunovion Pharmaceuticals Inc. Injectable Seizure Drugs Product
Table 94. Sunovion Pharmaceuticals Inc. Recent Developments/Updates
Table 95. H. Lundbeck A/S Corporation Information
Table 96. H. Lundbeck A/S Description and Business Overview
Table 97. H. Lundbeck A/S Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. H. Lundbeck A/S Injectable Seizure Drugs Product
Table 99. H. Lundbeck A/S Recent Developments/Updates
Table 100. GlaxoSmithKline plc Corporation Information
Table 101. GlaxoSmithKline plc Description and Business Overview
Table 102. GlaxoSmithKline plc Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. GlaxoSmithKline plc Injectable Seizure Drugs Product
Table 104. GlaxoSmithKline plc Recent Developments/Updates
Table 105. Sandoz Inc. Corporation Information
Table 106. Sandoz Inc. Description and Business Overview
Table 107. Sandoz Inc. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Sandoz Inc. Injectable Seizure Drugs Product
Table 109. Sandoz Inc. Recent Developments/Updates
Table 110. Omega Laboratories Ltd ERFA Canada 2012 Inc. Corporation Information
Table 111. Omega Laboratories Ltd ERFA Canada 2012 Inc. Description and Business Overview
Table 112. Omega Laboratories Ltd ERFA Canada 2012 Inc. Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Omega Laboratories Ltd ERFA Canada 2012 Inc. Injectable Seizure Drugs Product
Table 114. Omega Laboratories Ltd ERFA Canada 2012 Inc. Recent Developments/Updates
Table 115. Lundbeck Pharmaceuticals Llc Corporation Information
Table 116. Lundbeck Pharmaceuticals Llc Description and Business Overview
Table 117. Lundbeck Pharmaceuticals Llc Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Lundbeck Pharmaceuticals Llc Injectable Seizure Drugs Product
Table 119. Lundbeck Pharmaceuticals Llc Recent Developments/Updates
Table 120. Fresenius Kabi Corporation Information
Table 121. Fresenius Kabi Description and Business Overview
Table 122. Fresenius Kabi Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Fresenius Kabi Injectable Seizure Drugs Product
Table 124. Fresenius Kabi Recent Developments/Updates
Table 125. Mylan Pharmaceuticals Corporation Information
Table 126. Mylan Pharmaceuticals Description and Business Overview
Table 127. Mylan Pharmaceuticals Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Mylan Pharmaceuticals Injectable Seizure Drugs Product
Table 129. Mylan Pharmaceuticals Recent Developments/Updates
Table 130. Hoffmann La and Corporation Information
Table 131. Hoffmann La and Description and Business Overview
Table 132. Hoffmann La and Injectable Seizure Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Hoffmann La and Injectable Seizure Drugs Product
Table 134. Hoffmann La and Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Injectable Seizure Drugs Distributors List
Table 138. Injectable Seizure Drugs Customers List
Table 139. Injectable Seizure Drugs Market Trends
Table 140. Injectable Seizure Drugs Market Drivers
Table 141. Injectable Seizure Drugs Market Challenges
Table 142. Injectable Seizure Drugs Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Injectable Seizure Drugs
Figure 2. Global Injectable Seizure Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Injectable Seizure Drugs Market Share by Type in 2022 & 2029
Figure 4. Fosphenytoin Product Picture
Figure 5. Midazolam Product Picture
Figure 6. Carbamazepine Product Picture
Figure 7. Cenobamate Product Picture
Figure 8. Gabapentin Product Picture
Figure 9. Phenytoin Product Picture
Figure 10. Lamotrigine Product Picture
Figure 11. Topiramate Product Picture
Figure 12. Levetiracetam Product Picture
Figure 13. Others Product Picture
Figure 14. Global Injectable Seizure Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 15. Global Injectable Seizure Drugs Market Share by Application in 2022 & 2029
Figure 16. Hospital Pharmacies
Figure 17. Retail Pharmacies
Figure 18. Online Pharmacies
Figure 19. Others
Figure 20. Global Injectable Seizure Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 21. Global Injectable Seizure Drugs Market Size (2018-2029) & (US$ Million)
Figure 22. Global Injectable Seizure Drugs Sales (2018-2029) & (K Units)
Figure 23. Global Injectable Seizure Drugs Average Price (US$/Unit) & (2018-2029)
Figure 24. Injectable Seizure Drugs Report Years Considered
Figure 25. Injectable Seizure Drugs Sales Share by Manufacturers in 2022
Figure 26. Global Injectable Seizure Drugs Revenue Share by Manufacturers in 2022
Figure 27. The Global 5 and 10 Largest Injectable Seizure Drugs Players: Market Share by Revenue in 2022
Figure 28. Injectable Seizure Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 29. Global Injectable Seizure Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 30. North America Injectable Seizure Drugs Sales Market Share by Country (2018-2029)
Figure 31. North America Injectable Seizure Drugs Revenue Market Share by Country (2018-2029)
Figure 32. United States Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Canada Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Europe Injectable Seizure Drugs Sales Market Share by Country (2018-2029)
Figure 35. Europe Injectable Seizure Drugs Revenue Market Share by Country (2018-2029)
Figure 36. Germany Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. France Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. U.K. Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Italy Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Russia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Asia Pacific Injectable Seizure Drugs Sales Market Share by Region (2018-2029)
Figure 42. Asia Pacific Injectable Seizure Drugs Revenue Market Share by Region (2018-2029)
Figure 43. China Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Japan Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. South Korea Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. India Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Australia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. China Taiwan Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Indonesia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Thailand Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Malaysia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Latin America Injectable Seizure Drugs Sales Market Share by Country (2018-2029)
Figure 53. Latin America Injectable Seizure Drugs Revenue Market Share by Country (2018-2029)
Figure 54. Mexico Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Brazil Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Argentina Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Colombia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Middle East & Africa Injectable Seizure Drugs Sales Market Share by Country (2018-2029)
Figure 59. Middle East & Africa Injectable Seizure Drugs Revenue Market Share by Country (2018-2029)
Figure 60. Turkey Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 61. Saudi Arabia Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 62. UAE Injectable Seizure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 63. Global Sales Market Share of Injectable Seizure Drugs by Type (2018-2029)
Figure 64. Global Revenue Market Share of Injectable Seizure Drugs by Type (2018-2029)
Figure 65. Global Injectable Seizure Drugs Price (US$/Unit) by Type (2018-2029)
Figure 66. Global Sales Market Share of Injectable Seizure Drugs by Application (2018-2029)
Figure 67. Global Revenue Market Share of Injectable Seizure Drugs by Application (2018-2029)
Figure 68. Global Injectable Seizure Drugs Price (US$/Unit) by Application (2018-2029)
Figure 69. Injectable Seizure Drugs Value Chain
Figure 70. Injectable Seizure Drugs Production Process
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Distributors Profiles
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の注射用発作治療薬市場2022年：市場規模予測（～2028年）
  • 下剤の世界市場2023年：ポリエチレングリコール電解質、リン酸ナトリウム、硫酸マグネシウム、その他
  • 世界の注射用糖尿病治療薬市場2022年：市場規模予測（～2028年）
  • 世界の2型糖尿病用注射剤市場2022年：市場規模予測（～2028年）
  • 世界の腫瘍用ジェネリック注射剤市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7989 )"注射可能型発作治療薬の世界市場2023年：ホスフェニトイン、ミダゾラム、カルバマゼピン、セノバメート、ガバペンチン、フェニトイン、ラモトリジン、トピラメート、レベチラセタム、その他" (英文：Global Injectable Seizure Drugs Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。